eyeforpharma Philadelphia 2017: 6 in-depth conferences in one

eyeforpharma20 - 21 April 2017, Philadelphia, USA.
The democratization of healthcare is real, the healthcare delivery landscape is consolidating fast, and the patient is empowered and the customer in charge. Pharma needs to change and develop along with it. 6 in-depth commercial pharma conferences on the key issues of 2017 and beyond, the 6 eyeforpharma Philadelphia 2017 sessions will focus on:

Commercial Leadership

  • Commercial Leadership: Healthcare Leadership: How Pharma Embraces a New Customer Engagement Paradigm
  • Executive Commitment: Recognize Patient Centricity as a Journey: and Spearhead Cultural Change
  • Business Transformation: Your Company Needs to be Disrupted: Corporate Activism for Value Creation
  • Technology Partnerships: Tech meets Pharma: Life Science Partnerships from Bench to Bedside
  • Healthcare Challenges: Approaching the Caregiver Cliff: How Pharma Should Support the Supporters
  • The Implementation Panel: From Words to Action, How to Become a Pharma Intrapreneur

Patients as Partners

  • Patient advocacy 2.0: Manage ‘local customer engagement' from pre to post launch
  • The future of pharma-stakeholder collaboration: Lessons learnt from partnering in the rare disease field
  • Where rubber hits the road: Can patient centricity grow the bottom-line?
  • Case studies on understanding and acting on patient concern

Customer Experience

  • Is the new sales strategy to de-prioritize targets?
  • Customer experience is the key to commercial excellence
  • It's the experience that counts!
  • Look after your customer's journey from start to finish
  • Sales rep 2.0: The new portrait of a customer facing role

Commercial Model Innovation

  • A holistic commercial view: integrate your sales and marketing teams
  • Leverage untapped opportunities with patient-centric selling
  • Customer centricity is key. Are you doing enough?
  • The Modern Marketer: how to stay ahead in a competitive landscape

Pharma's Triple Aim

  • Strengthen the patient ecosystem - improve treatment adherence beyond physician support
  • How to innovate and differentiate your patient assistance solutions
  • Understand factors driving patients' treatment choices
  • Free your engagement from uncertainty around compliance

Digital Transformation

  • Maximize capabilities of your commercial teams with technology
  • Stay ahead of the curve: How digital integration takes your customer’s experience further
  • The power of integrating digital across all aspects of your organization
  • Leveraging Digital: Navigating digital trends and technologies to maximize positive outcomes for patients

Join the most forward thinking speakers from across North America including C-level, VPs and industry leaders from Shire, Otsuka, GSK, Novartis, Pfizer, Google, Sanofi, Takeda and many more. This is the ideal place to ensure your commercial strategy is prepared for 2017 and beyond.

World Pharma News readers can benefit from an exclusive discount - save $200 using our unique discount code WPN200 when you register online.

You can find full details of the meeting here.

About eyeforpharma
Our mission is to make pharma more open and valued. The ultimate driver for the pharmaceutical industry's health is meeting the needs of patients, otherwise it will cease to matter. For healthcare to be as good as it could be, the strength, skills and resources of our industry need to be fully integrated into health outcomes and we need pharma experience at the decision-making table. We believe the industry must focus on a business model combining service with product, with patients at the center.

Most Popular Now

Therapy using dual immune system cells effectively…

A newly developed immunotherapy that simultaneously uses modified immune-fighting cells to home in on and attack two antigens, or foreign substances, on cancer cells was ...

How to develop new drugs based on merged datasets

Polymorphs are molecules that have different molecular packing arrangements despite identical chemical compositions. In a recent paper, researchers at GlaxoSmithKline (GS...

New drug combination effective against SARS-CoV-2 …

More countries with greater resources are opening up for a more normal life. But COVID-19 and the SARS-CoV-2 virus are still a significant threat in large parts of the wo...

Cleveland Clinic study suggests steroid nasal spra…

A recent Cleveland Clinic study found that patients who regularly use steroid nasal sprays are less likely to develop severe COVID-19-related disease, including a 20 to 2...

Sanofi to focus its COVID-19 development efforts o…

Recent positive interim results of Sanofi's mRNA-based COVID-19 vaccine candidate Phase 1/2 study confirm the company's platform robust capabilities and strategy in mRNA...

Discovery of mechanics of drug targets for COVID-1…

A team of international researchers, including McGill Professor Stéphane Laporte, have discovered the working mechanism of potential drug targets for various diseases suc...

Phase II/III trial shows Ronapreve™ (casirivimab a…

Roche (SIX: RO, ROG; OTCQX: RHHBY) today confirmed positive data from the phase II/III 2066 study, investigating Ronapreve™ (casirivimab and imdevimab) in patients hospit...

Pfizer and BioNTech receive first U.S. FDA Emergen…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that the U.S. Food and Drug Administration (FDA) has authorized for emergency use a booster dose of the P...

AZD7442 request for Emergency Use Authorization fo…

AstraZeneca has submitted a request to the US Food and Drug Administration (FDA) for an Emergency Use Authorization (EUA) for AZD7442, its long-acting antibody (LAAB) com...

Pfizer and BioNTech receive CHMP positive opinion …

Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") today announced that the Committee for Medicinal Products for Human Use (CHMP) of the Europea...

Boehringer Ingelheim acquires Abexxa Biologics to …

Boehringer Ingelheim announced the acquisition of Abexxa Biologics Inc., a biopharmaceutical company taking a new approach in the fields of immuno-oncology and oncology r...

GSK welcomes WHO recommendation for broad roll-out…

GlaxoSmithKline (GSK) plc welcomes and applauds the WHO recommendation for the broader deployment of GSK's RTS,S malaria vaccine to reduce childhood illness and deaths fr...